Literature DB >> 21326279

Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis?

Mark E Molitch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21326279     DOI： 10.1038/nrendo.2011.33

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

2.  Prolactinomas and pregnancy.

Authors:  Mark E Molitch
Journal:  Clin Endocrinol (Oxf)       Date:  2010-06-09       Impact factor: 3.478

3.  The cabergoline-resistant prolactinoma patient: new challenges.

Authors:  Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2008-12       Impact factor: 5.958

Review 4.  Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.

Authors:  Vania dos Santos Nunes; Regina El Dib; César Luiz Boguszewski; Célia Regina Nogueira
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

5.  Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Authors:  A Colao; A Di Sarno; F Sarnacchiaro; D Ferone; G Di Renzo; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

Review 6.  Advances in the treatment of prolactinomas.

Authors:  Mary P Gillam; Mark E Molitch; Gaetano Lombardi; Annamaria Colao
Journal:  Endocr Rev       Date:  2006-05-26       Impact factor: 19.871

7.  Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.

Authors:  Pallavi Iyer; Mark E Molitch
Journal:  Endocr Pract       Date:  2011 May-Jun       Impact factor: 3.443

8.  Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.

Authors:  Masami Ono; Nobuhiro Miki; Takakazu Kawamata; Rena Makino; Kosaku Amano; Toshiro Seki; Osami Kubo; Tomokatsu Hori; Kazue Takano
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

Review 9.  Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.

Authors:  Olaf M Dekkers; Joep Lagro; Pia Burman; Jens Otto Jørgensen; Johannes A Romijn; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2009-10-30       Impact factor: 5.958

Review 10.  Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis.

Authors:  E Michael Lewiecki; Neil Binkley
Journal:  Endocr Pract       Date:  2009 Sep-Oct       Impact factor: 3.443
  10 in total
  3 in total

1.  How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.

Authors:  Z Karaca; S Yarman; I Ozbas; P Kadioglu; M Akturk; F Kilicli; H S Dokmetas; R Colak; H Atmaca; Z Canturk; Y Altuntas; N Ozbey; N Hatipoglu; F Tanriverdi; K Unluhizarci; F Kelestimur
Journal:  J Endocrinol Invest       Date:  2017-06-20       Impact factor: 4.256

Review 2.  Treatment of hyperprolactinemia in post-menopausal women: pros.

Authors:  D Iacovazzo; L De Marinis
Journal:  Endocrine       Date:  2014-08-12       Impact factor: 3.633

3.  Pharmacoeconomic aspects of the treatment of pituitary gland tumours.

Authors:  Jerzy Sowiński; Nadia Sawicka; Katarzyna Piątek; Ariadna Zybek; Marek Ruchała
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.